AMED250117C70000
- 0.00
- 0.000.00%
Amedisys Newsroom
Truist Financial Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Neurocrine (NBIX) and Amedisys (AMED)
Truist Financial Maintains Amedisys(AMED.US) With Hold Rating, Announces Target Price $101
Truist Financial Keeps Their Hold Rating on Amedisys (AMED)
TD Cowen Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
Truist Financial Maintains Amedisys(AMED.US) With Hold Rating
TD Cowen Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
TD Cowen Sticks to Its Hold Rating for Amedisys (AMED)
Amedisys Price Target Maintained With a $101.00/Share by Deutsche Bank
Deutsche Bank Downgrades Amedisys to Hold, Maintains Price Target to $101
Amedisys Analyst Ratings
TD Cowen Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
Deutsche Bank Downgrades Amedisys to Hold From Buy, Price Target Is $101
TD Cowen Initiates Amedisys(AMED.US) With Hold Rating, Announces Target Price $101
Amedisys: Hold Rating Affirmed Amidst Modest EBITDA Adjustments and Acquisition Offer
Amedisys Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Amedisys, Maintains $101 Price Target
TD Cowen Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
Amedisys (AMED) Gets a Hold From TD Cowen
Truist Financial Maintains Amedisys(AMED.US) With Hold Rating